The startup develops genetic medicines utilizing genome editing and engineering techniques to create pharmaceutical and biological preparations for human therapeutics. This approach enables researchers to effectively target and modify genetic disorders, improving treatment outcomes for patients.
Funding
$25.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetic disorders lack effective treatments, leaving patients with limited options and reduced quality of life. Traditional pharmaceutical approaches often fail to address the root cause of these diseases, which stem from errors in the genetic code. This necessitates the development of novel therapeutic strategies that can directly target and correct disease-causing genes.
Solution
Enceladus Bio is developing genetic medicines using genome editing and engineering technologies to create targeted human therapeutics. Their approach focuses on precisely modifying disease-causing genes to restore normal function and improve patient outcomes. By leveraging advanced genome editing techniques, Enceladus Bio aims to create pharmaceutical and biological preparations that offer a more effective and potentially curative approach to treating genetic disorders. This technology has the potential to address a wide range of inherited diseases and significantly improve the lives of affected individuals.
Target Audience
The primary target audience includes patients suffering from genetic disorders and the healthcare providers who treat them.
Features
- Utilizes advanced genome editing technologies for precise gene modification.
- Focuses on developing targeted therapeutics for genetic disorders.
- Aims to correct the root cause of genetic diseases at the DNA level.
- Creates pharmaceutical and biological preparations for human use.